Analyst Consensus ?
ConsensusBuy31 ratings
Bullish3096.8%
Neutral00.0%
Bearish13.2%
Guardant Health, Inc. · GH · FY2026 Q3 · Calendar Q4 2026
Guardant Health raises 2026 outlook as Shield growth accelerates
The supplied Q3 analysis supports a growth case built on expansion across oncology, screening and biopharma/data, with Shield growth and broader payer coverage as important contributors. The raised outlook and cost-reduction work are constructive, but the thesis depends on sustained demand, reimbursement progress and successful regulatory execution.
Why did GH fall 9.0% after beating EPS estimates in FY2026 Q3?
Research this report with FN2. Free to start; review your question before sending.
Reported After market closeNASDAQHealthcare
$20.59B market cap
100quality score
Earnings scorecard
Reported versus consensus
Reported EPS
$-0.29
Consensus $-0.75
EPS surprise
+61.3%
Reported versus consensus
Reported revenue
$361.0M
Consensus $350.7M
Revenue surprise
+2.9%
Reported versus consensus
Market reaction
close-to-close (session unavailable)
Stock move
-9.0%
Event window
SPY move
-4.4%
Same window
Abnormal move
-4.6%
Stock minus SPY
Volume
2.3×
Versus trailing sessions
Subsequent drift
0.0%
Up to 20 sessions
GHSPY benchmark
Ask FN2 about GH FY2026 Q3
Choose a question to continue your research
Why did GH fall 9.0% after beating EPS estimates in FY2026 Q3?What changed in GH's guidance and outlook in FY2026 Q3?Give me the bull and bear case for GH after FY2026 Q3 earnings.
Free to start. Your question opens in chat for you to review and send. FN2 can look up the transcript, financials and prior quarters.
Transcript intelligence
What changed
Management raised its full-year 2026 revenue outlook to $1.36–$1.37 billion from the prior quarter's $1.34–$1.36 billion range. The supplied analysis also describes revenue growth as accelerating across segments and Shield revenue growth of 180%.
Guidance delta
Full-year 2026 revenue guidance increased to $1.36–$1.37 billion. The supplied analysis also cites a 65% non-GAAP gross-margin target; it does not provide a prior-quarter comparison for that target.
Key takeaways
- The supplied Q3 analysis reports revenue up 36%, with growth across oncology, screening and biopharma/data.
- Shield revenue grew 180%, and management described payer-coverage expansion adding about 30 million lives.
- Management highlighted FDA approval for Guardant360 CDx for ESR1 mutations, Wave 4 Smart Apps and the Reveal Ultra launch.
- The analysis cites a lower-cost Shield workflow that brought cost per test to $330, ahead of schedule.
Management priorities
- Expand Shield commercial reach and coverage, including planned national direct-to-consumer campaigns in 2027.
- Advance Guardant360 Tissue through PMA submission and pursue relevant regulatory and reimbursement milestones.
- Continue Shield cost reduction, including commissioning a new automated Palo Alto lab and targeting $200 per test by end-2028.
Follow GH with an agent that reads every filing, transcript, and price print. Free to start.
Try FN2 freeEarnings History
Estimate
Beat
Miss
Match
Analyst 52W Price Targets
$148.96Current
$28Low
$154.85Average
$225High
Latest persisted target per named analyst; persisted current price from FN2's market snapshot as of Nov 6, 2026. Not an FN2 forecast.
Firm-level rating actions
FMP grade actions identify the grading firm, not a named analyst.
| Firm | Rating | Prior rating | Action | Date |
|---|---|---|---|---|
| BTIG | Buy | Buy | Maintain | Oct 27, 2026 |
| Morgan Stanley | Overweight | Overweight | Maintain | Oct 13, 2026 |
| Barclays | Overweight | Overweight | Maintain | Oct 7, 2026 |
| Guggenheim | Buy | Buy | Maintain | Oct 1, 2026 |
| UBS | Buy | Buy | Maintain | Sep 9, 2026 |
| Stephens & Co. | Overweight | Overweight | Maintain | Aug 4, 2026 |
| Piper Sandler | Overweight | Overweight | Maintain | Aug 4, 2026 |
| Stifel | Buy | Buy | Maintain | Aug 3, 2026 |
| TD Cowen | Buy | Buy | Maintain | Jul 31, 2026 |
| RBC Capital | Outperform | Outperform | Maintain | Jul 31, 2026 |
| Mizuho | Outperform | Outperform | Maintain | Jul 31, 2026 |
| JP Morgan | Overweight | Overweight | Maintain | Jul 31, 2026 |
| Canaccord Genuity | Buy | Buy | Maintain | Jul 14, 2026 |
| Citigroup | Buy | Buy | Maintain | Jul 8, 2026 |
| Evercore ISI Group | Outperform | Outperform | Maintain | Jul 6, 2026 |
| B of A Securities | Buy | Buy | Maintain | Jul 6, 2026 |
| Bernstein | Outperform | Outperform | Maintain | Jul 2, 2026 |
| Goldman Sachs | Buy | Buy | Maintain | Jun 5, 2026 |
| Wells Fargo | Overweight | Overweight | Maintain | Feb 20, 2026 |
| Leerink Partners | Outperform | Outperform | Maintain | Feb 20, 2026 |
| Wolfe Research | Outperform | Peer Perform | Upgrade | Sep 25, 2025 |
| Scotiabank | Sector Outperform | Sector Outperform | Maintain | Jul 31, 2025 |
| Raymond James | Outperform | Outperform | Maintain | Jul 31, 2025 |
| TD Securities | Buy | Buy | Maintain | May 1, 2025 |
| Craig-Hallum | Buy | Buy | Maintain | Aug 8, 2024 |
| Credit Suisse | Outperform | Outperform | Maintain | May 10, 2023 |
| OTR Global | Negative | Mixed | Downgrade | May 1, 2023 |
| Cowen & Co. | Outperform | Outperform | Maintain | Feb 24, 2023 |
| SVB Leerink | Outperform | Outperform | Maintain | Feb 24, 2022 |
| Bank of America | Buy | Neutral | Upgrade | Apr 10, 2019 |
| William Blair | Outperform | Outperform | Maintain | Oct 29, 2018 |
Named analyst price targets
Upside is calculated against the persisted current price $148.96. FMP does not supply a rating on these named-analyst rows.
| Firm | Analyst | 52W target | Price when posted | Upside | Date |
|---|---|---|---|---|---|
| BTIG | Mark Massaro | $210 | $173.25 | +41.0% | Oct 27, 2026 |
| Morgan Stanley | Kallum Titchmarsh | $200 | $162.99 | +34.3% | Oct 12, 2026 |
| Barclays | Luke Sergott | $220 | $170.69 | +47.7% | Oct 7, 2026 |
| Guggenheim | Analyst unavailable | $200 | $177.24 | +34.3% | Oct 1, 2026 |
| Bernstein | Eve Burstein | $210 | $161.25 | +41.0% | Sep 10, 2026 |
| UBS | Analyst unavailable | $225 | $160.98 | +51.0% | Sep 9, 2026 |
| Redburn Partners | Analyst unavailable | $203 | $161.41 | +36.3% | Sep 8, 2026 |
| Morgan Stanley | Analyst unavailable | $185 | $160.36 | +24.2% | Aug 4, 2026 |
| Stephens | Analyst unavailable | $195 | $158.83 | +30.9% | Aug 4, 2026 |
| Piper Sandler | Analyst unavailable | $193 | $158.83 | +29.6% | Aug 4, 2026 |
| RBC Capital | Dan Leonard | $200 | $161.87 | +34.3% | Jul 31, 2026 |
| RBC Capital | Analyst unavailable | $210 | $161 | +41.0% | Jul 31, 2026 |
| Stifel Nicolaus | Daniel Arias | $180 | $152.35 | +20.8% | Jul 31, 2026 |
| Goldman Sachs | Analyst unavailable | $210 | $152.35 | +41.0% | Jul 31, 2026 |
| Mizuho Securities | Anthony Petrone | $200 | $152.35 | +34.3% | Jul 31, 2026 |
| BTIG | Mark Massaro | $195 | $152.35 | +30.9% | Jul 31, 2026 |
| Barclays | Analyst unavailable | $200 | $152.35 | +34.3% | Jul 31, 2026 |
| Guggenheim | Analyst unavailable | $190 | $162.96 | +27.6% | Jul 16, 2026 |
| Canaccord Genuity | Kyle Mikson | $205 | $158.4 | +37.6% | Jul 14, 2026 |
| Morgan Stanley | Analyst unavailable | $175 | $156.17 | +17.5% | Jul 9, 2026 |
| Evercore ISI | Vijay Kumar | $200 | $169.45 | +34.3% | Jul 6, 2026 |
| Bernstein | Eve Burstein | $200 | $170.77 | +34.3% | Jul 2, 2026 |
| BTIG | Analyst unavailable | $190 | $170.19 | +27.6% | Jul 1, 2026 |
| Guggenheim | Analyst unavailable | $160 | $149.22 | +7.4% | Jun 29, 2026 |
| UBS | Analyst unavailable | $150 | $130.83 | +0.7% | Jun 24, 2026 |
| RBC Capital | Dan Leonard | $185 | $130.9 | +24.2% | Jun 11, 2026 |
| Mizuho Securities | Analyst unavailable | $175 | $125.61 | +17.5% | Jun 8, 2026 |
| Goldman Sachs | Evie Koslosky | $165 | $133.06 | +10.8% | Jun 5, 2026 |
| Evercore ISI | Analyst unavailable | $160 | $129.14 | +7.4% | Jun 2, 2026 |
| BTIG | Analyst unavailable | $160 | $127.41 | +7.4% | May 27, 2026 |
| BTIG | Mark Massaro | $155 | $118.95 | +4.1% | May 26, 2026 |
| Piper Sandler | Analyst unavailable | $127 | $119.32 | -14.7% | May 21, 2026 |
| Piper Sandler | David Westenberg | $135 | $96.71 | -9.4% | May 12, 2026 |
| Barclays | Luke Sergott | $115 | $82.21 | -22.8% | Apr 14, 2026 |
| Piper Sandler | Analyst unavailable | $130 | $94.42 | -12.7% | Feb 24, 2026 |
| Raymond James | Analyst unavailable | $129 | $97.49 | -13.4% | Feb 23, 2026 |
| Evercore ISI | Analyst unavailable | $110 | $106.84 | -26.2% | Feb 20, 2026 |
| BTIG | Analyst unavailable | $145 | $106.38 | -2.7% | Feb 20, 2026 |
| Stifel Nicolaus | Analyst unavailable | $130 | $106.38 | -12.7% | Feb 20, 2026 |
| Canaccord Genuity | Analyst unavailable | $135 | $106.38 | -9.4% | Feb 20, 2026 |
| Barclays | Analyst unavailable | $130 | $106.38 | -12.7% | Feb 20, 2026 |
| Robert W. Baird | Catherine Schulte | $120 | $104.85 | -19.4% | Feb 17, 2026 |
| UBS | Analyst unavailable | $175 | $111 | +17.5% | Jan 30, 2026 |
| Guggenheim | Analyst unavailable | $135 | $115.69 | -9.4% | Jan 26, 2026 |
| Stifel Nicolaus | Analyst unavailable | $120 | $108.74 | -19.4% | Jan 9, 2026 |
| Mizuho Securities | Analyst unavailable | $135 | $108.74 | -9.4% | Jan 9, 2026 |
| Guggenheim | Subbu Nambi | $115 | $99 | -22.8% | Jan 5, 2026 |
| Evercore ISI | Vijay Kumar | $105 | $101.74 | -29.5% | Jan 5, 2026 |
| Canaccord Genuity | Analyst unavailable | $125 | $99.74 | -16.1% | Dec 22, 2025 |
| Mizuho Securities | Analyst unavailable | $120 | $100 | -19.4% | Dec 17, 2025 |
| Leerink Partners | Analyst unavailable | $155 | $104 | +4.1% | Dec 15, 2025 |
| Wells Fargo | Brandon Couillard | $120 | $102.04 | -19.4% | Dec 15, 2025 |
| Barclays | Analyst unavailable | $120 | $102.04 | -19.4% | Dec 15, 2025 |
| BTIG | Analyst unavailable | $140 | $101.34 | -6.0% | Dec 12, 2025 |
| Morgan Stanley | Tejas Savant | $130 | $105.22 | -12.7% | Dec 1, 2025 |
| UBS | Dan Leonard | $110 | $95.29 | -26.2% | Oct 30, 2025 |
| BTIG | Mark Massaro | $100 | $95.55 | -32.9% | Oct 30, 2025 |
| Mizuho Securities | Bradley Bowers | $100 | $72.27 | -32.9% | Oct 30, 2025 |
| Canaccord Genuity | Kyle Mikson | $100 | $72.27 | -32.9% | Oct 30, 2025 |
| Barclays | Analyst unavailable | $85 | $72.27 | -42.9% | Oct 30, 2025 |
| Piper Sandler | Analyst unavailable | $90 | $67.51 | -39.6% | Oct 22, 2025 |
| Barclays | Analyst unavailable | $70 | $62.65 | -53.0% | Oct 2, 2025 |
| Canaccord Genuity | Kyle Mikson | $75 | $60.18 | -49.7% | Sep 26, 2025 |
| Stifel Nicolaus | Analyst unavailable | $70 | $60.18 | -53.0% | Sep 25, 2025 |
| BTIG | Mark Massaro | $80 | $60.75 | -46.3% | Sep 25, 2025 |
| Stifel Nicolaus | Daniel Arias | $73 | $62.64 | -51.0% | Sep 25, 2025 |
| Wolfe Research | Doug Schenkel | $75 | $61.23 | -49.7% | Sep 25, 2025 |
| China Renaissance Securities (US) Inc. | Tempus AI | $70 | $49.9 | -53.0% | Jun 25, 2025 |
| Morgan Stanley | Analyst unavailable | $52 | $42.66 | -65.1% | Mar 5, 2025 |
| UBS | Dan Leonard | $40 | $27.68 | -73.1% | Aug 21, 2024 |
| Craig-Hallum | Bill Bonello | $37 | $31.36 | -75.2% | Aug 8, 2024 |
| Jefferies | Tycho Peterson | $40 | $33.96 | -73.1% | Aug 8, 2024 |
| BTIG | Mark Massaro | $50 | $35.28 | -66.4% | Jul 29, 2024 |
| Guggenheim | Subbu Nambi | $36 | $28.88 | -75.8% | Jun 28, 2024 |
| Canaccord Genuity | Kyle Mikson | $38 | $27.41 | -74.5% | Jun 4, 2024 |
| Jefferies | Tycho Peterson | $32 | $27.1 | -78.5% | Jun 3, 2024 |
| BTIG | Mark Massaro | $45 | $22.51 | -69.8% | May 23, 2024 |
| Canaccord Genuity | Kyle Mikson | $30 | $23.01 | -79.9% | May 22, 2024 |
| Craig-Hallum | Chase Knickerbocker | $28 | $17.94 | -81.2% | Apr 24, 2024 |
| Piper Sandler | David Westenberg | $40 | $27.59 | -73.1% | Sep 27, 2023 |
| Goldman Sachs | Analyst unavailable | $45 | $29.56 | -69.8% | Feb 6, 2023 |
| Morgan Stanley | Tejas Savant | $80 | $41.26 | -46.3% | Dec 16, 2022 |
| Canaccord Genuity | Kyle Mikson | $65 | $41.26 | -56.4% | Dec 16, 2022 |
| Stephens | Mason Carrico | $99 | $59.78 | -33.5% | Oct 5, 2022 |
| Goldman Sachs | Analyst unavailable | $80 | $54.25 | -46.3% | Aug 8, 2022 |
| J.P. Morgan | Julia Qin | $125 | $39.32 | -16.1% | May 9, 2022 |
| Goldman Sachs | Matthew Sykes | $160 | $117.9 | +7.4% | Jun 3, 2021 |
Track every rating change on GH the moment it posts. Free to start.
Start freeCompany context
Snapshot as of publicationGuardant Health, Inc., established in Redwood City, California, in 2011, is a precision oncology company that delivers a range of diagnostic blood tests, comprehensive data sets, and advanced analytical solutions both within the United States and internationally. For patients with advanced-stage cancer, the company's core offerings include several liquid biopsy-based tests such as Guardant360 (available in LDT and CDx versions) and GuardantOMNI. Complementing these diagnostic tools, Guardant Health also provides GuardantINFORM, an in-silico research platform leveraging an extensive clinical-genomic liquid biopsy dataset derived from advanced cancer patients. Innovation is a key focus, with the company currently developing the LUNAR-2 test, designed for the early detection of colorectal cancer in eligible asymptomatic individuals.…
Healthcare peers this season
Latest reports in the same sector| Company | Quarter | EPS surprise | Market move | Headline |
|---|---|---|---|---|
| MRNA Moderna, Inc. | FY2026 Q3 · Calendar Q4 2026 | — | +7.3% | Moderna raises 2026 outlook as vaccines and oncology advance |
| MTD Mettler-Toledo International Inc. | FY2026 Q3 · Calendar Q4 2026 | +3.6% | +4.8% | Mettler-Toledo raises growth outlook after Q3 strength led by China |
| ELAN Elanco Animal Health Incorporated | FY2026 Q3 · Calendar Q4 2026 | — | +6.2% | Elanco lifts 2026 outlook as innovation products drive Q3 growth |
| GMAB Genmab A/S | FY2026 Q3 · Calendar Q4 2026 | +55.6% | -4.3% | Genmab pairs nine-month growth with a heavier launch agenda |
| NTRA Natera, Inc. | FY2026 Q3 · Calendar Q4 2026 | -49.3% | -15.2% | Natera raises 2026 revenue outlook as Signatera drives Q3 growth |
| STE STERIS plc | FY2027 Q2 · Calendar Q4 2026 | +9.7% | +2.5% | STERIS raises FY2027 EPS outlook after 9% revenue growth |
Latest beats and misses
Who reports nextBeat on EPS
- FNFFY2026 Q3 · November 5, 20260.0% EPS+6.6% move
- MTDFY2026 Q3 · November 5, 2026+3.6% EPS+4.8% move
- IAGFY2026 Q3 · November 5, 2026+16.7% EPS+4.6% move
- GMABFY2026 Q3 · November 5, 2026+55.6% EPS-4.3% move
- STEFY2027 Q2 · November 4, 2026+9.7% EPS+2.5% move
- IRMFY2026 Q3 · November 5, 2026+4.6% EPS-11.1% move
Missed on EPS
- VMRKFY2026 Q3 · November 4, 2026-425.6% EPS+2.4% move
- NTRAFY2026 Q3 · November 5, 2026-49.3% EPS-15.2% move
- TIGOFY2026 Q3 · November 5, 2026-40.8% EPS+2.6% move
- UHALFY2027 Q2 · November 4, 2026-15.4% EPS-3.2% move
- LAMRFY2026 Q3 · November 5, 2026-3.6% EPS-0.8% move
- CMIFY2026 Q3 · November 5, 2026-6.0% EPS-4.9% move
Get the GH recap when the next report posts
One email per quarter with the scorecard, the market reaction and what changed on the call. No account needed.
Sources
- Earnings call transcript and parsed analysis · 2026-11-06T06:16:34.553995+00:00
- FN2 earnings calendar · 2026-11-06T01:23:16.275024+00:00
- Polygon adjusted daily market bars · 2026-11-06T09:40:45.921941+00:00
- Financial Modeling Prep analyst price-target consensus and quote snapshot · 2026-11-06T09:40:45.919318+00:00
Methodology
Reported and consensus figures come from FN2's earnings event records. Market reaction and volume are calculated from daily adjusted bars around the event; abnormal move subtracts the SPY move over the same window.
Analyst target low, average, and high values are derived at request time from each named analyst's latest persisted FMP target. The current-price marker comes from FN2's persisted market snapshot. They are sell-side estimates, not an FN2 valuation or recommendation.
Transcript intelligence is a structured synthesis of the current and prior earnings-call analyses. Missing values stay missing and are never estimated.
By FN2 Research · Updated · As of 2026-11-06. For educational purposes only; not investment advice.